{{EngvarB|date=September 2013}}
{{Use dmy dates|date=September 2013}}
{{Infobox company
 | name = ViiV Healthcare
 | logo = [[File:ViiV logo.gif|75px]]
 | type = Joint venture
 | genre =
 | foundation = {{start date|df=yes|2009|11}}
 | founder =
 | location = [[Brentford]], [[Greater London]], UK
 | area_served = Global
 | key_people = Deborah Waterhouse, ([[Chief executive officer|CEO]]), replaced Dominique Limet in April 2017
 | industry = Healthcare
 | products = [[Pharmaceutical]]s
 | services =
 | revenue =
 | operating_income =
 | net_income =
 | assets =
 | equity =
 | owner =
 | num_employees =
 | parent = {{unbulleted list|[[GlaxoSmithKline]] (76.5%)|[[Pfizer]] (13.5%)|[[Shionogi]] (10%)}}
 | divisions =
 | subsid =
 | slogan =
 | homepage ={{Official website|http://www.viivhealthcare.com/}}
 | footnotes =
 | intl =
}}

'''ViiV Healthcare''' ({{IPAc-en|v|iː|v}} {{respell|VEEV}}) is a pharmaceutical company specialising in the development of therapies for HIV infection that was created as a joint venture by [[Pfizer]] and [[GlaxoSmithKline]] in November 2009 with both companies transferring their HIV assets to the new company.<ref name = "jacksft1">Jacks, Andrew [http://www.ft.com/cms/s/0/5327ff12-2aaa-11de-8415-00144feabdc0.html "GSK and Pfizer to Merge HIV Portfolios] Financial Times. 16 April 2010 {{subscription required}}</ref> In 2012 [[Shionogi]] joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer and 10% by Shionogi.<ref>{{cite web|url=http://www.viivhealthcare.com/media/press-releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercialise-and-develop-integrase-inhibitor-portfolio.aspx | title = Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio | publisher = viivhealthcare.com | date = | accessdate = 7 March 2014}}</ref> This ownership structure may change depending upon the achievement of certain milestones.<ref name="jacksft1" />

ViiV Healthcare's products have a market share of approximately 19%<ref>[http://www.viivhealthcare.com/about-us/at-a-glance.aspx "ViiV Healthcare Company Website. About Us — At a Glance"] {{webarchive | url = https://web.archive.org/web/20101209234228/http://www.viivhealthcare.com/about-us/at-a-glance.aspx | date = 9 December 2010}} Accessed 13 October 2010</ref> of the global HIV market, which makes it the second largest healthcare company, following after [[Gilead Sciences]], that is working on the treatment of HIV.<ref>Jacks, Andrew [http://www.ft.com/cms/s/0/d4af5df8-c8ae-11de-8f9d-00144feabdc0.html "ViiV Vows Joint Venture Will Help Fight HIV"] Financial Times. 3 November 2009 {{subscription required}}</ref>

ViiV Healthcare's headquarters are in Brentford in the United Kingdom and it has sites in a number of other countries including; the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.<ref>[http://www.viivhealthcare.com/about-us/locations.aspx "ViiV Healthcare Company Website. About Us — Locations"] {{webarchive | url = https://web.archive.org/web/20101209232622/http://www.viivhealthcare.com/about-us/locations.aspx | date = 9 December 2010}} Accessed 13 October 2010</ref>

==Products==
The company currently markets 12 products:<ref>[https://www.viivhealthcare.com/our-medicines.aspx ViiV Healthcare Company Website. Our Medicines.] {{webarchive | url = https://web.archive.org/web/20170228113958/https://www.viivhealthcare.com/our-medicines.aspx | date = 28 February 2017}} Accessed 21 July 2017</ref><ref>McNeil, Donald [https://www.nytimes.com/2009/11/10/health/10glob.html?_r=1&scp=1&sq=ViiV&st=cse "AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease"] New York Times. 9 November 2009</ref>

* [[Reverse-transcriptase_inhibitor#Nucleoside_analog_reverse-transcriptase_inhibitors_.28NARTIs_or_NRTIs.29|Nucleoside reverse transcriptase inhibitors (NRTIs)]]:
** [[abacavir]] (brand name Ziagen)
** [[lamivudine]] (brand names Epivir and 3TC)
** [[zidovudine]] (brand name Retrovir and AZT)
* [[Reverse-transcriptase_inhibitor#Non-nucleoside_reverse-transcriptase_inhibitors_.28NNRTIs.29|Non-nucleoside reverse transcriptase inhibitors (NNRTIs)]]:
** [[delavirdine]] (brand name Rescriptor)
* [[Integrase inhibitor|Integrase strand transfer inhibitors (INSTIs)]]:
** [[dolutegravir]] (brand name Tivicay)
* [[Protease inhibitor (pharmacology)|Protease inhibitors]]:
** [[fosamprenavir]] (brand names Lexiva and Telzir)
** [[nelfinavir]] (brand name Viracept)
* [[Entry inhibitor]]s:
** [[maraviroc]] (brand names Selzentry and Celsentri)
* [[Fixed-dose combination (antiretroviral)|Antiretroviral fixed-dose combinations]], including two single-pill regimens:
** [[abacavir/lamivudine]] (brand names Epzicom and Kivexa)
** [[abacavir/lamivudine/zidovudine]] (brand name Trizivir)
** [[lamivudine/zidovudine]] (brand name Combivir)
** [[abacavir/dolutegravir/lamivudine]] (brand name Triumeq)

== Treatment access programs ==
ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low and middle income countries, as well as all of [[Sub-Saharan Africa]].<ref name="viivhealthcare.com">[https://www.viivhealthcare.com/what-we-do/we-improve-access-to-our-medicines.aspx "ViiV Healthcare Company Website. We Improve Access to Our Medicines"] Accessed 12 January 2014</ref>

The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.<ref name="viivhealthcare.com"/><ref>Reuters [https://web.archive.org/web/20100723095923/http://www.africagoodnews.com:80/health/glaxo-pfizer-jv-opens-hiv-pipeline-to-generic-companies.html "Glaxo, Pfizer JV Opens HIV Pipeline to Generic Companies"] Africa — the Good News. 19 July 2010</ref>

==See also==
* [[Pharmaceutical industry in the United Kingdom]]

==References==
{{Reflist}}

{{GlaxoSmithKline}}
{{Pharmaceutical industry in the United Kingdom}}

[[Category:Companies established in 2009]]
[[Category:GlaxoSmithKline]]
[[Category:Joint ventures]]
[[Category:Pharmaceutical companies of the United Kingdom]]
[[Category:Pfizer]]